- Home
- REI vs MSLE Comparison
REI vs MSLE Comparison
Compare REI & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | REI | MSLE |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.3M | 146.9M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | REI | MSLE |
|---|---|---|
| Price | $1.26 | $6.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.4M | 29.4K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $307,178,072.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $5.50 |
| 52 Week High | $2.00 | $13.39 |
Technical Indicators
Market Signals| Indicator | REI | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 38.74 | 47.73 |
| Support Level | $1.22 | $6.73 |
| Resistance Level | $1.64 | $8.59 |
| Average True Range (ATR) | 0.09 | 0.50 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 0.91 | 29.69 |
Price Performance
Historical ComparisonAbout REI Ring Energy Inc.
Ring Energy Inc is an independent exploration and production company based in The Woodlands, Texas and is engaged in oil and natural gas development, production, acquisition, and exploration activities currently focused in the Permian Basin of Texas. The drilling operations of the company target the oil and liquid rich producing formations in the Northwest Shelf, the Central Basin Platform and the Delaware Basin all of which are part of the Permian Basin in Texas.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.